NL300339I2 - Sulfonamidederivaten als progeneesmiddelen van aspartylproteaseremmers - Google Patents
Sulfonamidederivaten als progeneesmiddelen van aspartylproteaseremmersInfo
- Publication number
- NL300339I2 NL300339I2 NL300339C NL300339C NL300339I2 NL 300339 I2 NL300339 I2 NL 300339I2 NL 300339 C NL300339 C NL 300339C NL 300339 C NL300339 C NL 300339C NL 300339 I2 NL300339 I2 NL 300339I2
- Authority
- NL
- Netherlands
- Prior art keywords
- prodrugs
- protease inhibitors
- sulfonamide derivatives
- aspartyl protease
- aspartyl
- Prior art date
Links
- 239000003696 aspartic proteinase inhibitor Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 229940124530 sulfonamide Drugs 0.000 title 1
- 150000003456 sulfonamides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
- C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
- C07F9/65844—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a five-membered ring which may be condensed with another ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/998,050 US6436989B1 (en) | 1997-12-24 | 1997-12-24 | Prodrugs of aspartyl protease inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NL300339I1 NL300339I1 (nl) | 2008-06-02 |
| NL300339I2 true NL300339I2 (nl) | 2009-11-02 |
Family
ID=25544691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300339C NL300339I2 (nl) | 1997-12-24 | 2008-03-26 | Sulfonamidederivaten als progeneesmiddelen van aspartylproteaseremmers |
Country Status (43)
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122000A1 (en) * | 1981-01-07 | 2004-06-24 | Vertex Pharmaceuticals Incorporated. | Inhibitors of aspartyl protease |
| UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AP1411A (en) | 1998-06-02 | 2005-05-10 | Osi Pharm Inc | Pyrrolo[2,3d] pyrimidine compositions and their use. |
| US6878716B1 (en) | 1998-06-02 | 2005-04-12 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptor and uses thereof |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| GB9815567D0 (en) * | 1998-07-18 | 1998-09-16 | Glaxo Group Ltd | Antiviral compound |
| AU6329599A (en) * | 1998-09-28 | 2000-04-17 | Glaxo Group Limited | Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester |
| GB9914821D0 (en) * | 1999-06-24 | 1999-08-25 | Glaxo Group Ltd | Compounds |
| US7160890B2 (en) | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| ES2275866T3 (es) | 2001-02-14 | 2007-06-16 | Tibotec Pharmaceuticals Ltd. | 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih. |
| PL367084A1 (en) | 2001-04-09 | 2005-02-21 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors |
| ATE429431T1 (de) | 2001-05-11 | 2009-05-15 | Tibotec Pharm Ltd | 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren |
| US7576084B2 (en) * | 2001-10-12 | 2009-08-18 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
| AU2002360436A1 (en) | 2001-11-30 | 2003-06-17 | Osi Pharmaceuticals, Inc. | 2-aryl pyrrologpyrimidines for a1 and a3 receptors |
| TWI286476B (en) * | 2001-12-12 | 2007-09-11 | Tibotec Pharm Ltd | Combination of cytochrome P450 dependent protease inhibitors |
| US20030229067A1 (en) | 2001-12-20 | 2003-12-11 | Arlindo Castelhano | Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use |
| CA2471059C (en) | 2001-12-20 | 2011-04-26 | Osi Pharmaceuticals, Inc. | Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| PL216539B1 (pl) | 2001-12-21 | 2014-04-30 | Tibotec Pharm Ltd | Związki fenylosulfonylowe i zastosowanie związków fenylosulfonylowych |
| MY142238A (en) | 2002-03-12 | 2010-11-15 | Tibotec Pharm Ltd | Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors |
| US7157489B2 (en) * | 2002-03-12 | 2007-01-02 | The Board Of Trustees Of The University Of Illinois | HIV protease inhibitors |
| AU2003231766A1 (en) * | 2002-04-26 | 2003-11-10 | Gilead Sciences, Inc. | Non nucleoside reverse transcriptase inhibitors |
| CN100582097C (zh) | 2002-05-17 | 2010-01-20 | 泰博特克药品有限公司 | 取代的苯并异噁唑磺酰胺广谱hiv蛋白酶抑制剂 |
| NZ538714A (en) | 2002-08-14 | 2007-03-30 | Tibotec Pharm Ltd | Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| CA2425031A1 (en) * | 2003-04-01 | 2004-10-01 | Smithkline Beecham Corporation | Pharmaceutical compositions |
| US7470724B2 (en) | 2003-04-25 | 2008-12-30 | Gilead Sciences, Inc. | Phosphonate compounds having immuno-modulatory activity |
| WO2005002626A2 (en) | 2003-04-25 | 2005-01-13 | Gilead Sciences, Inc. | Therapeutic phosphonate compounds |
| KR20060022647A (ko) | 2003-04-25 | 2006-03-10 | 길리애드 사이언시즈, 인코포레이티드 | 키나아제 억제 포스포네이트 유사체 |
| US7407965B2 (en) | 2003-04-25 | 2008-08-05 | Gilead Sciences, Inc. | Phosphonate analogs for treating metabolic diseases |
| US7452901B2 (en) | 2003-04-25 | 2008-11-18 | Gilead Sciences, Inc. | Anti-cancer phosphonate analogs |
| US7432261B2 (en) | 2003-04-25 | 2008-10-07 | Gilead Sciences, Inc. | Anti-inflammatory phosphonate compounds |
| ATE490788T1 (de) | 2003-04-25 | 2010-12-15 | Gilead Sciences Inc | Antivirale phosphonate analoge |
| WO2004096285A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Anti-infective phosphonate conjugates |
| US7427636B2 (en) | 2003-04-25 | 2008-09-23 | Gilead Sciences, Inc. | Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| US20050143352A1 (en) | 2003-07-09 | 2005-06-30 | Paratek Pharmaceuticals, Inc. | Substituted tetracycline compounds |
| JP4738333B2 (ja) * | 2003-07-09 | 2011-08-03 | パラテック ファーマシューティカルズ インコーポレイテッド | ９−アミノメチルテトラサイクリン化合物のプロドラッグ |
| US20050119163A1 (en) | 2003-09-18 | 2005-06-02 | The Government Of The United States Of America, As Represented By The Secretary, | SH2 domain binding inhibitors |
| WO2005044279A1 (en) | 2003-10-24 | 2005-05-19 | Gilead Sciences, Inc. | Purine nucleoside phosphonate conjugates |
| US7432273B2 (en) | 2003-10-24 | 2008-10-07 | Gilead Sciences, Inc. | Phosphonate analogs of antimetabolites |
| US7834043B2 (en) * | 2003-12-11 | 2010-11-16 | Abbott Laboratories | HIV protease inhibiting compounds |
| US20050131042A1 (en) * | 2003-12-11 | 2005-06-16 | Flentge Charles A. | HIV protease inhibiting compounds |
| US8193227B2 (en) | 2003-12-11 | 2012-06-05 | Abbott Laboratories | HIV protease inhibiting compounds |
| EP2153832B1 (en) * | 2003-12-15 | 2016-03-09 | Merck Sharp & Dohme Corp. | Heterocyclic aspartyl protease inhibitors |
| WO2005058913A1 (en) | 2003-12-18 | 2005-06-30 | Janssen Pharmaceutica N.V. | Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents |
| JP2007515495A (ja) | 2003-12-22 | 2007-06-14 | ギリアード サイエンシーズ， インコーポレイテッド | ４’−置換カルボビル誘導体およびアバカビル誘導体ならびにｈｉｖおよびｈｃｖ抗ウイルス活性を有する関連化合物 |
| ES2402552T3 (es) | 2004-07-06 | 2013-05-06 | Abbott Laboratories | Profármacos de inhibidores de proteasa de VIH |
| DE602005027466D1 (de) | 2004-07-27 | 2011-05-26 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
| ES2575871T3 (es) * | 2004-08-02 | 2016-07-01 | Ambrilia Biopharma Inc. | Composiciones farmacéuticas que comprende un compuesto a base de lisina y un agente antiviral o antirretroviral VIH |
| US7388008B2 (en) * | 2004-08-02 | 2008-06-17 | Ambrilia Biopharma Inc. | Lysine based compounds |
| EP1789107B1 (en) | 2004-08-30 | 2009-05-27 | Interstitial Therapeutics | Medical stent provided with inhibitors of atp synthesis |
| US20080125432A1 (en) | 2004-12-01 | 2008-05-29 | Devgen Nv | 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family |
| NI200700147A (es) | 2004-12-08 | 2019-05-10 | Janssen Pharmaceutica Nv | Derivados de quinazolina inhibidores de cinasas dirigidos a multip |
| EP1938691A3 (en) | 2004-12-17 | 2009-07-22 | Devgen NV | Nematicidal compositions |
| ATE451381T1 (de) * | 2005-01-19 | 2009-12-15 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| US20080194554A1 (en) * | 2005-03-11 | 2008-08-14 | Mclean Ed W | Hiv Protease Inhibitors |
| AR053845A1 (es) | 2005-04-15 | 2007-05-23 | Tibotec Pharm Ltd | 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450 |
| WO2006114001A1 (en) | 2005-04-27 | 2006-11-02 | Ambrilia Biopharma Inc. | Method for improving pharmacokinetics of protease inhibitors and protease inhibitor precursors |
| US8003627B2 (en) | 2005-10-21 | 2011-08-23 | Universiteit Antwerpen | Urokinase inhibitors |
| AR058238A1 (es) | 2005-11-28 | 2008-01-23 | Tibotec Pharm Ltd | Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih |
| TWI385173B (zh) | 2005-11-28 | 2013-02-11 | Tibotec Pharm Ltd | 作為ｈｉｖ蛋白酶抑制劑之經取代的胺基苯基磺醯胺化合物 |
| ES2452718T3 (es) * | 2005-11-30 | 2014-04-02 | Taimed Biologics, Inc. | Profármacos a base de lisina de inhibidores de la aspartil proteasa y procesos para su preparación |
| KR20140087058A (ko) | 2005-11-30 | 2014-07-08 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| AU2006319358B2 (en) | 2005-11-30 | 2012-01-19 | AbbVie Deutschland GmbH & Co. KG | Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies |
| EP2674436A1 (en) | 2005-12-27 | 2013-12-18 | Otsuka Pharmaceutical Co., Ltd. | Water-soluble benzoazepine compound and its pharmaceutical composition |
| AU2007274284B2 (en) | 2006-07-13 | 2012-04-26 | Janssen Pharmaceutica N.V. | Mtki quinazoline derivatives |
| EP3056509A1 (en) | 2006-09-08 | 2016-08-17 | Piramal Imaging SA | Bombesin analogues for use in diagnosis |
| US8410300B2 (en) * | 2006-09-21 | 2013-04-02 | Taimed Biologics, Inc. | Protease inhibitors |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| CN101631568B (zh) * | 2007-03-12 | 2012-08-22 | 尼克塔治疗公司 | 低聚物-蛋白酶抑制剂偶联物 |
| DK2185562T3 (en) | 2007-07-27 | 2016-02-22 | Janssen Pharmaceutica Nv | PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES |
| EP2053033A1 (en) | 2007-10-26 | 2009-04-29 | Bayer Schering Pharma AG | Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors |
| EP2100900A1 (en) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin analog peptide antagonist conjugates |
| DK2283024T3 (da) | 2008-03-10 | 2013-08-05 | Janssen Pharmaceutica Nv | 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer |
| EP2262538B1 (en) * | 2008-03-12 | 2014-12-10 | Nektar Therapeutics | Oligomer-amino acid conjugate |
| EP2116236A1 (en) | 2008-04-21 | 2009-11-11 | Université de Mons-Hainaut | Bisbenzamidine derivatives for use as antioxidant |
| US8658617B2 (en) | 2008-07-08 | 2014-02-25 | Gilead Sciences, Inc. | Salts of HIV inhibitor compounds |
| CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
| US20120135965A1 (en) * | 2009-05-20 | 2012-05-31 | Ranbaxy Laboratories Limited | Amorphous fosamprenavir calcium |
| JP2012530069A (ja) | 2009-06-12 | 2012-11-29 | ネクター セラピューティックス | プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体 |
| AU2010296846B2 (en) | 2009-09-16 | 2013-11-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of fosamprenavir calcium |
| WO2011061590A1 (en) | 2009-11-17 | 2011-05-26 | Hetero Research Foundation | Novel carboxamide derivatives as hiv inhibitors |
| WO2011061295A1 (en) | 2009-11-19 | 2011-05-26 | Blue Medical Devices Bv | Narrow profile composition-releasing expandable medical balloon catheter |
| WO2011085130A1 (en) | 2010-01-07 | 2011-07-14 | Pliva Hrvatska D.O.O. | Solid state forms of fosamprenavir calcium salt and process for preparation thereof |
| ES2670811T3 (es) | 2010-01-27 | 2018-06-01 | Viiv Healthcare Company | Terapia antivírica |
| US20110223131A1 (en) | 2010-02-24 | 2011-09-15 | Gilead Sciences, Inc. | Antiviral compounds |
| US20110224443A1 (en) * | 2010-03-15 | 2011-09-15 | Venkata Naga Brahmeshwara Rao Mandava | Preparation of fosamprenavir calcium |
| WO2011114212A1 (en) | 2010-03-19 | 2011-09-22 | Lupin Limited | Ammonium, calcium and tris salts of fosamprenavir |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| WO2011141515A1 (en) | 2010-05-14 | 2011-11-17 | Bayer Pharma Aktiengesellschaft | Diagnostic agents for amyloid beta imaging |
| WO2011158259A1 (en) | 2010-06-18 | 2011-12-22 | Matrix Laboratories Ltd | Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof |
| US8785648B1 (en) | 2010-08-10 | 2014-07-22 | The Regents Of The University Of California | PKC-epsilon inhibitors |
| WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
| EP2614055A2 (en) * | 2010-09-10 | 2013-07-17 | Lupin Limited | Process for preparation of substantially pure fosamprenavir calcium and its intermediates |
| GB201019043D0 (en) | 2010-11-10 | 2010-12-22 | Protea Biopharma N V | Use of 2',5'-oligoadenylate derivative compounds |
| WO2012085625A1 (en) | 2010-12-21 | 2012-06-28 | Lupin Limited | Process for the preparation of fosamprenavir calcium and intermediate used in its preparation |
| JP2014513044A (ja) * | 2011-02-10 | 2014-05-29 | マイラン ラボラトリーズ リミテッド | ホスアンプレナビルカルシウム結晶およびその調製方法 |
| ES2923573T3 (es) | 2011-06-21 | 2022-09-28 | Alnylam Pharmaceuticals Inc | Composiciones de ARNi de proteína 3 de tipo angiopoyetina (ANGPTL3) y métodos de uso de las mismas |
| WO2012178033A2 (en) | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| US9309213B2 (en) | 2011-07-11 | 2016-04-12 | Purdue Research Foundation | C-3 substituted bicyclooctane based HIV protease inhibitors |
| WO2013011485A1 (en) | 2011-07-20 | 2013-01-24 | Ranbaxy Laboratories Limited | Process for the preparation of sulfonamides useful as retroviral protease inhibitors |
| US9233943B2 (en) | 2012-01-10 | 2016-01-12 | Council Of Scientific & Industrial Research | Process for synthesis of syn azido epdxide and its use as intermediate for the synthesis of amprenavir and saquinavir |
| US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
| EP2700396A3 (en) | 2012-06-20 | 2015-04-29 | Sylphar Nv | Strip for the delivery of oral care compositions |
| US9877981B2 (en) | 2012-10-09 | 2018-01-30 | President And Fellows Of Harvard College | NAD biosynthesis and precursors for the treatment and prevention of cancer and proliferation |
| JP2015536940A (ja) | 2012-10-29 | 2015-12-24 | シプラ・リミテッド | 抗ウイルス性ホスホネート類似体及びその製造方法 |
| HUE035887T2 (en) | 2012-12-05 | 2018-05-28 | Alnylam Pharmaceuticals Inc | PCSK9 iRNA preparations and methods for their use |
| PE20211393A1 (es) | 2013-03-14 | 2021-07-27 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO |
| IL285780B (en) | 2013-05-22 | 2022-07-01 | Alnylam Pharmaceuticals Inc | Preparations of tmprss6 irna and methods of using them |
| DK2999785T3 (en) | 2013-05-22 | 2018-07-23 | Alnylam Pharmaceuticals Inc | SERPINA1-IRNA COMPOSITIONS AND PROCEDURES FOR USE THEREOF |
| WO2015089368A2 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| AU2015217301A1 (en) | 2014-02-11 | 2016-08-25 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA compositions and methods of use thereof |
| WO2015175510A1 (en) | 2014-05-12 | 2015-11-19 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating a serpinc1-associated disorder |
| EP3146049B1 (en) | 2014-05-22 | 2020-02-26 | Alnylam Pharmaceuticals, Inc. | Angiotensinogen (agt) irna compositions and methods of use thereof |
| EP3180003B1 (en) | 2014-07-01 | 2022-01-12 | The Regents of the University of California | Pkc-epsilon inhibitors |
| WO2016001907A1 (en) | 2014-07-02 | 2016-01-07 | Prendergast Patrick T | Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents. |
| JP6522732B2 (ja) | 2014-07-11 | 2019-05-29 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖを治療するためのトール様受容体の調節因子 |
| EP3191591A1 (en) | 2014-09-12 | 2017-07-19 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
| EP3212196A4 (en) | 2014-10-29 | 2018-07-11 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of hiv protease |
| EP3212794B1 (en) | 2014-10-30 | 2021-04-07 | Genzyme Corporation | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| WO2016083490A1 (en) | 2014-11-27 | 2016-06-02 | Remynd Nv | Compounds for the treatment of amyloid-associated diseases |
| JP2018510621A (ja) | 2015-02-13 | 2018-04-19 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法 |
| MX2017013102A (es) | 2015-04-13 | 2018-02-23 | Alnylam Pharmaceuticals Inc | Composiciones de ácido ribonucleico de interferencia (arni) de angiopoyetina-tipo 3 (angptl3) y método de uso de las mismas. |
| PL3288637T3 (pl) | 2015-04-28 | 2022-12-19 | Newsouth Innovations Pty Limited | Kierowanie nad+ do leczenia indukowanych chemioterapią i radioterapią zaburzenia funkcji poznawczych, neuropatii i nieaktywności |
| TWI806034B (zh) | 2015-05-06 | 2023-06-21 | 美商阿尼拉製藥公司 | 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法 |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| EP3350328A1 (en) | 2015-09-14 | 2018-07-25 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof |
| EP3349757A1 (en) | 2015-09-15 | 2018-07-25 | Gilead Sciences, Inc. | Modulators of toll-like recptors for the treatment of hiv |
| TWI836281B (zh) | 2015-12-07 | 2024-03-21 | 美商健贊公司 | 治療ｓｅｒｐｉｎｃ１相關疾患之方法及組成物 |
| JP2018536689A (ja) | 2015-12-10 | 2018-12-13 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | ステロール調節エレメント結合タンパク質（ＳＲＥＢＰ）シャペロン（ＳＣＡＰ）ｉＲＮＡ組成物およびその使用方法 |
| WO2017214518A1 (en) | 2016-06-10 | 2017-12-14 | Alnylam Pharmaceuticals, Inc. | COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
| TWI788312B (zh) | 2016-11-23 | 2023-01-01 | 美商阿尼拉製藥公司 | 絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法 |
| TW202317151A (zh) | 2016-12-16 | 2023-05-01 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白（ＴＴＲ）ｉＲＮＡ組成物於治療或預防ＴＴＲ相關疾病之方法 |
| WO2018206760A1 (en) | 2017-05-11 | 2018-11-15 | Remynd N.V. | Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders |
| US11564921B2 (en) | 2017-07-21 | 2023-01-31 | Viiv Healthcare Company | Regimens for treating HIV infections and AIDS |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| CA3078971A1 (en) | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| TW202023574A (zh) | 2018-08-13 | 2020-07-01 | 美商阿尼拉製藥公司 | Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法 |
| TW202043471A (zh) | 2019-01-16 | 2020-12-01 | 美商健贊公司 | ＳＥＲＰＩＮＣ１ ｉＲＮＡ組成物及其使用方法 |
| WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
| AU2021225333A1 (en) | 2020-02-24 | 2022-08-11 | Katholieke Universiteit Leuven | Pyrrolopyridine and imidazopyridine antiviral compounds |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| EP4267579A1 (en) | 2020-12-22 | 2023-11-01 | Luxembourg Institute of Health (LIH) | Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases |
| WO2022184898A1 (en) | 2021-03-04 | 2022-09-09 | Universiteit Antwerpen | Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer |
| CN117500772A (zh) | 2021-05-31 | 2024-02-02 | 泰利克斯制药(创新)私人有限公司 | 改进的前列腺特异性膜抗原靶向放射性药物及其用途 |
| WO2023021132A1 (en) | 2021-08-18 | 2023-02-23 | Katholieke Universiteit Leuven | 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues |
| WO2023046900A1 (en) | 2021-09-23 | 2023-03-30 | Katholieke Universiteit Leuven | Ribonucleoside analogues against -sars-cov-2 |
| WO2023241799A1 (en) | 2022-06-15 | 2023-12-21 | Université Libre de Bruxelles | Flavanols for use in the treatment of retroviral infections |
| WO2024062043A1 (en) | 2022-09-21 | 2024-03-28 | Universiteit Antwerpen | Substituted phenothiazines as ferroptosis inhibitors |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3743722A (en) | 1971-07-14 | 1973-07-03 | Abbott Lab | Anti-coagulant isolation |
| FR2459235A1 (fr) | 1979-06-14 | 1981-01-09 | Sanofi Sa | Nouveaux derives de sulfonyl-aniline, leur procede de preparation et leur application therapeutique |
| JPS5946252A (ja) | 1982-09-09 | 1984-03-15 | Dainippon Ink & Chem Inc | 含フツ素アミノカルボキシレ−トおよびその製法 |
| JPS5948449A (ja) | 1982-09-13 | 1984-03-19 | Dainippon Ink & Chem Inc | 直鎖状含フツ素アニオン化合物およびその製造方法 |
| JPS6171830A (ja) | 1984-09-17 | 1986-04-12 | Dainippon Ink & Chem Inc | 界面活性剤組成物 |
| US4616088A (en) | 1984-10-29 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitor |
| US4629724A (en) | 1984-12-03 | 1986-12-16 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitors |
| DE3635907A1 (de) | 1986-10-22 | 1988-04-28 | Merck Patent Gmbh | Hydroxy-aminosaeurederivate |
| NL8800100A (nl) | 1987-01-21 | 1988-08-16 | Sandoz Ag | Nieuwe peptidederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
| CA1340588C (en) | 1988-06-13 | 1999-06-08 | Balraj Krishan Handa | Amino acid derivatives |
| IL91780A (en) | 1988-10-04 | 1995-08-31 | Abbott Lab | History of the amine of the xenon-preventing xanine acid, the process for their preparation and the pharmaceutical preparations containing them |
| WO1990007329A1 (en) | 1989-01-06 | 1990-07-12 | The Regents Of The University Of California | Selection method for pharmacologically active compounds |
| US5354866A (en) * | 1989-05-23 | 1994-10-11 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5151438A (en) | 1989-05-23 | 1992-09-29 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| IE902295A1 (en) | 1989-07-07 | 1991-01-16 | Abbott Lab | Amino acid analog cck antagonists |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| WO1991018866A2 (en) | 1990-06-01 | 1991-12-12 | The Du Pont Merck Pharmaceutical Company | 1,4-diamino-2,3-dihydroxybutanes |
| TW225540B (US06559137-20030506-C00071.png) | 1990-06-28 | 1994-06-21 | Shionogi & Co | |
| DK0813867T3 (da) | 1990-11-19 | 2005-10-03 | Monsanto Co | Retrovirale proteaseinhibitorer |
| JPH06502859A (ja) | 1990-11-19 | 1994-03-31 | モンサント カンパニー | レトロウイルスプロテアーゼ阻害剤 |
| ATE136888T1 (de) | 1990-11-19 | 1996-05-15 | Monsanto Co | Retrovirale proteaseinhibitoren |
| DK0735019T3 (da) | 1990-11-19 | 2000-10-23 | Monsanto Co | Retrovirale proteaseinhibitorer |
| IE913840A1 (en) | 1990-11-20 | 1992-05-20 | Abbott Lab | Retroviral protease inhibiting compounds |
| ES2112880T3 (es) | 1991-11-08 | 1998-04-16 | Merck & Co Inc | Inhibidores de la proteasa de vih utiles para el tratamiento del sida. |
| AU4253193A (en) | 1992-05-20 | 1993-12-13 | G.D. Searle & Co. | Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors |
| EP0641325B1 (en) | 1992-05-21 | 2001-03-07 | Monsanto Company | Retroviral protease inhibitors |
| DK0656886T3 (da) | 1992-08-25 | 1998-02-02 | Searle & Co | N-(Alkanoylamino-2-hydroxypropyl)-sulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
| ES2112430T3 (es) | 1992-08-25 | 1998-04-01 | Searle & Co | Sulfonilalcanoilamino hidroxietilamino sulfonamidas utiles como inhibidores de proteasas retroviricas. |
| DE69321845T2 (de) | 1992-08-25 | 1999-04-29 | Searle & Co | Hydroxyethylaminosulfonamide verwendbar als inhibitoren retroviraler proteasen |
| ES2137998T3 (es) * | 1992-09-03 | 2000-01-01 | Boehringer Ingelheim Pharma | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. |
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| US5723490A (en) * | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
| US5783701A (en) * | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
| TW372972B (en) | 1992-10-23 | 1999-11-01 | Novartis Ag | Antiretroviral acyl compounds |
| WO1994010136A1 (en) | 1992-10-30 | 1994-05-11 | G.D. Searle & Co. | Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors |
| CA2142997A1 (en) | 1992-10-30 | 1994-05-11 | Michael L. Vazquez | Hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors |
| US5484926A (en) | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| AU6135294A (en) | 1993-02-12 | 1994-08-29 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| JP3419539B2 (ja) | 1993-02-17 | 2003-06-23 | 中外製薬株式会社 | インドリン−２−オン誘導体 |
| DK0715618T3 (da) | 1993-08-24 | 1999-08-23 | Searle & Co | Hydroxyethylaminosulfonamider til anvendelse som inhibitorer af retrovirale proteaser |
| IL110898A0 (en) | 1993-09-10 | 1994-11-28 | Narhex Australia Pty Ltd | Polar-substituted hydrocarbons |
| IL111584A0 (en) | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
| US5527829A (en) | 1994-05-23 | 1996-06-18 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| DE19506742A1 (de) | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
| US5691372A (en) | 1995-04-19 | 1997-11-25 | Vertex Pharmaceuticals Incorporated | Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease |
| US5750493A (en) | 1995-08-30 | 1998-05-12 | Raymond F. Schinazi | Method to improve the biological and antiviral activity of protease inhibitors |
| US5646180A (en) | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
| US6180634B1 (en) | 1997-11-13 | 2001-01-30 | Merck & Co., Inc. | Combination therapy for the treatment of AIDS |
| US6436989B1 (en) * | 1997-12-24 | 2002-08-20 | Vertex Pharmaceuticals, Incorporated | Prodrugs of aspartyl protease inhibitors |
| AU2092599A (en) * | 1997-12-24 | 1999-07-19 | Vertex Pharmaceuticals Incorporated | Prodrugs of aspartyl protease inhibitors |
| CO5261510A1 (es) * | 1999-02-12 | 2003-03-31 | Vertex Pharma | Inhibidores de aspartil proteasa |
-
1997
- 1997-12-24 US US08/998,050 patent/US6436989B1/en not_active Expired - Lifetime
-
1998
- 1998-03-09 SK SK966-2000A patent/SK287123B6/sk not_active IP Right Cessation
- 1998-03-09 CN CNA2009101453192A patent/CN101565412A/zh active Pending
- 1998-03-09 CZ CZ20002363A patent/CZ301653B6/cs not_active IP Right Cessation
- 1998-03-09 PL PL342113A patent/PL202845B1/pl unknown
- 1998-03-09 BR BR9814480-4A patent/BR9814480A/pt not_active Application Discontinuation
- 1998-03-09 EE EEP200000385A patent/EE04466B1/xx unknown
- 1998-03-09 AU AU65466/98A patent/AU755087B2/en not_active Expired
- 1998-03-09 WO PCT/US1998/004595 patent/WO1999033815A1/en active Application Filing
- 1998-03-09 RS YU39800A patent/RS52483B/en unknown
- 1998-03-09 ME MEP-820/08A patent/MEP82008A/xx unknown
- 1998-03-09 IL IL13694198A patent/IL136941A0/xx active IP Right Review Request
- 1998-03-09 KR KR10-2000-7007113A patent/KR100520737B1/ko not_active IP Right Cessation
- 1998-03-09 EA EA200000703A patent/EA003509B1/ru not_active IP Right Cessation
- 1998-03-09 HU HU0101831A patent/HU229596B1/hu active Protection Beyond IP Right Term
- 1998-03-09 ID IDW20001413A patent/ID24962A/id unknown
- 1998-03-09 NZ NZ505776A patent/NZ505776A/xx not_active IP Right Cessation
- 1998-03-09 AP APAP/P/2000/001850A patent/AP1172A/en active
- 1998-03-09 TR TR2000/02615T patent/TR200002615T2/xx unknown
- 1998-03-09 CN CNB988132338A patent/CN100503589C/zh not_active Expired - Lifetime
- 1998-03-10 DE DE69838903T patent/DE69838903T2/de not_active Expired - Lifetime
- 1998-03-10 EP EP98104292A patent/EP0933372B1/en not_active Expired - Lifetime
- 1998-03-10 DE DE122008000021C patent/DE122008000021I2/de active Active
- 1998-03-10 PT PT98104292T patent/PT933372E/pt unknown
- 1998-03-10 EP EP07024817A patent/EP1944300A3/en not_active Withdrawn
- 1998-03-10 JP JP05870598A patent/JP3736964B2/ja not_active Expired - Lifetime
- 1998-03-10 DK DK98104292T patent/DK0933372T3/da active
- 1998-03-10 CA CA002231700A patent/CA2231700C/en not_active Expired - Lifetime
- 1998-03-10 AT AT98104292T patent/ATE382042T1/de active
- 1998-03-10 SI SI9830903T patent/SI0933372T1/sl unknown
- 1998-03-10 ES ES98104292T patent/ES2299193T3/es not_active Expired - Lifetime
- 1998-09-03 UA UA2000074456A patent/UA72733C2/uk unknown
- 1998-12-22 MY MYPI98005827A patent/MY131525A/en unknown
- 1998-12-22 TW TW087121460A patent/TW486474B/zh not_active IP Right Cessation
- 1998-12-23 AR ARP980106679A patent/AR017965A1/es active IP Right Grant
- 1998-12-23 ZA ZA9811830A patent/ZA9811830B/xx unknown
- 1998-12-23 PE PE1998001275A patent/PE20000048A1/es not_active IP Right Cessation
- 1998-12-23 CO CO98076458A patent/CO4990992A1/es unknown
-
2000
- 2000-02-03 HK HK00100695A patent/HK1021737A1/xx not_active IP Right Cessation
- 2000-06-22 IL IL136941A patent/IL136941A/en not_active IP Right Cessation
- 2000-06-22 IS IS5546A patent/IS2817B/is unknown
- 2000-06-23 US US09/602,494 patent/US6559137B1/en not_active Expired - Lifetime
- 2000-06-23 NO NO20003304A patent/NO326265B1/no not_active IP Right Cessation
- 2000-06-23 OA OA1200000187A patent/OA11468A/en unknown
- 2000-07-24 BG BG104631A patent/BG64869B1/bg unknown
-
2003
- 2003-02-19 US US10/370,171 patent/US6838474B2/en not_active Expired - Lifetime
-
2004
- 2004-10-04 US US10/958,223 patent/US7592368B2/en not_active Expired - Fee Related
-
2005
- 2005-07-13 JP JP2005205007A patent/JP4282639B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-26 NL NL300339C patent/NL300339I2/nl unknown
- 2008-04-02 LU LU91426C patent/LU91426I2/fr unknown
- 2008-04-17 FR FR08C0015C patent/FR08C0015I2/fr active Active
-
2009
- 2009-01-27 JP JP2009016033A patent/JP2009102400A/ja not_active Withdrawn
- 2009-04-22 NO NO2009008C patent/NO2009008I2/no not_active IP Right Cessation
- 2009-07-16 US US12/504,243 patent/US20100124543A1/en not_active Abandoned
-
2014
- 2014-07-18 HU HUS1400042C patent/HUS1400042I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300339I2 (nl) | Sulfonamidederivaten als progeneesmiddelen van aspartylproteaseremmers | |
| EE200000386A (et) | Aspartüülproteaasi inhibiitorite eelravimid | |
| PT1086076E (pt) | Inibidores de sulfonamida de aspartil protease | |
| EE9700266A (et) | Aspartüüli proteaasi THF-i sisaldavad sulfoonamiidinhibiitorid | |
| NO974744D0 (no) | Oksygenert-heterocykelinneholdende sulfonamidhemmere av aspartylprotease | |
| NO990548D0 (no) | Inhibitorer for cystein-protease | |
| NO993587D0 (no) | Sulfonamid-metalloprotease-inhibitorer | |
| NO20006716D0 (no) | Proteaseinhibitorer | |
| ATE264339T1 (de) | Serine protease inhibitoren | |
| NO20016034D0 (no) | Inhibitorer av aspartylprotease | |
| NO995434L (no) | Proteaseinhibitorer | |
| NO995435D0 (no) | Protease-inhibitorer | |
| ATE277074T1 (de) | Serine-protease-inhibitoren | |
| NO995268D0 (no) | Proteaseinhibitorer | |
| DE69714222D1 (de) | Serine-protease-inhibitoren | |
| BR9612344A (pt) | Inibidores de proteases | |
| MA26429A1 (fr) | Inhibiteurs de protease |